AZothBio(에이조스바이오)

Delivery Solution Provider

Our delivery solution generates optimized peptides and LNPs to targeting cellular organelles.
We are continually improving its delivering accuracy and expending its cargo types.

Pipelines by DDiSTA

Pipeline	PDF	Indication	Status	Brief MOA
AZBT51105 T Cell Vaccine	PDF다운	Cancer Vaccine / Virus Vaccine	First-in-Class	Using immunotherapy to recognize and eliminate cancer cells
AZBR52209 siRNA Delivery Peptide	PDF다운	RNAi Therapy	First-in-Class	Prevent disease-causing mutations of protein by targeted gene inhibition
AZBE53206 ER Targeting Peptide	PDF다운	ER Stress related Disease	First-in-Class	Intervening in ER stress and modulating signaling components of the UPR

Pipeline

PDF

Indication

Status

Brief MOA

AZBT51105

T Cell Vaccine

PDF다운

Cancer Vaccine / Virus Vaccine

First-in-Class

Using immunotherapy to recognize and eliminate
cancer cells

AZBR52209

siRNA Delivery Peptide

PDF다운

RNAi Therapy

First-in-Class

Prevent disease-causing mutations of protein by targeted gene inhibition

AZBE53206

ER Targeting Peptide

PDF다운

ER Stress related Disease

First-in-Class

Intervening in ER stress and modulating signaling components of the UPR

As of 2022.Q2

Pipeline Schedule

Pipeline	2021				2022				2023				2024
Pipeline	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
AZBT51105	In vitro In vivo Pre-clinical
AZBT51105	License out
AZBR52209	Target analysis In vitro In vivo Pre-clinical
AZBR52209	License out
AZBE53206	Target analysis In vitro In vivo Pre-clinical
AZBE53206	License out

DDiSTA Based Solution

- Prediction of CPP sequence and LNPs for Efficient Drug Delivery into Specific Organelles

In silico

Step 1
Sequencing Profiling

Sequence & Structure

Propensity Score

Optimization
Step 2
Screening

3D Structure

Properties and Stability

Overall score

In vitro & In vivo

Step 3
POC Verification

In-House Lab Assay

CRO & Research Partners